Developing First-In-Class INPP5A Inhibitors as the First Effective Therapy for All GNAQ/11 Mutated Metastatic Uveal Melanoma Patients

• Unité de recherche: INNOSUISSE
• Numéro de projet: 125.999 IP-LS
• Titre du projet anglais: Developing First-In-Class INPP5A Inhibitors as the First Effective Therapy for All GNAQ/11 Mutated Metastatic Uveal Melanoma Patients

Mots-clé (Anglais)

Life sciences, Human medicine

Résumé des résultats (Abstract) (Anglais)

We aim to develop first-in-class effective small molecule inhibitor therapy for GNAQ/11 mutated uveal melanoma, the most common and lethal eye cancer. We found a novel and cancer specific target for a clearly defined patient population in this disease with high unmet need for therapeutics.